Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Brolucizumab vs Aflibercept in Ophthalmic Disease (Japan, Phase 2-3)
jRCT2080224987Phase 3Completed
- Start
- Dec 2019
- Modality
- scFv Fragments → Antibody Fragments → Engineered Antibody Formats → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
01
Overview
Phase 3, randomised trial of brolucizumab in retinal vascular disease (2 arms). Started Dec 2019; status: completed.
02
Drugs
brolucizumab
03
Conditions
retinal vascular disease
Beyond the preview
Go deeper on jRCT2080224987.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080224987.